Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Medical Error Proposal Requires Reporting “Near-Misses” Within 15 Days

Executive Summary

FDA's proposed safety reporting requirements would require reports on "near misses" of medical errors within 15 days
Advertisement

Related Content

FDA’s Adverse Event Reporting Rule Would Generate “Noise,” PhRMA Says
Iressa Clears FDA: Phase IV Symptom Trial Will Be First Shot At Full Approval
FDA Plan Seeks Better, Not Burdensome, Data Collection, McClellan Says
FDA Patient Safety Strategy Would Shift AE Monitoring To Automated Systems
Foreign Safety Data Sought By FDA Under Proposed Rule On Periodic Updates
Foreign Safety Data Sought By FDA Under Proposed Rule On Periodic Updates
FDA Drug Safety Rule Would Promote Premarketing Adverse Event Reports
Rx Name Risk Assessments Should Be Conducted By Manufacturers, FDA Says
Rx Name Risk Assessments Should Be Conducted By Manufacturers, FDA Says
Patient Safety Bills: House Commerce Cmte. Goes First, Requires Bar Codes
Advertisement
UsernamePublicRestriction

Register

PS041475

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel